id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-N-0832-0057,FDA,FDA-2016-N-0832,Letter from Phibro Animal Health Corporation,Other,Letter(s),2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T15:57:53Z,,0,0,0900006482d83a18
FDA-2016-N-0832-0056,FDA,FDA-2016-N-0832,"Letter from FDA to Covington & Burling, LLP - Extention letter",Other,Extension of Time,2017-12-20T05:00:00Z,2017,12,2017-12-20T05:00:00Z,,2017-12-20T20:00:06Z,,0,0,0900006482d43d53
FDA-2016-N-0832-0055,FDA,FDA-2016-N-0832,Letter from FDA to Phibro Animal Health Corporation,Other,Letter(s),2017-10-31T04:00:00Z,2017,10,2017-10-31T04:00:00Z,,2017-10-31T13:43:18Z,,0,0,0900006482c291cc
FDA-2016-N-0832-0054,FDA,FDA-2016-N-0832,Information Request Letter to Phibro (Covington and Burling)7-12-17,Other,Request,2017-07-24T04:00:00Z,2017,7,2017-07-24T04:00:00Z,,2017-07-24T14:44:46Z,,0,0,090000648291374d
FDA-2016-N-0832-0053,FDA,FDA-2016-N-0832,Carbadox Letter May 1,Other,Response(s),2017-05-02T04:00:00Z,2017,5,2017-05-02T04:00:00Z,,2017-05-02T21:04:49Z,,0,0,090000648258bedb
FDA-2016-N-0832-0052,FDA,FDA-2016-N-0832,Confidential Letter from Center for Veterinary Medicine Recommendation to the Office of Scientific Integrity,Other,Response(s),2017-04-25T04:00:00Z,2017,4,2017-04-25T04:00:00Z,,2017-04-25T16:52:07Z,,0,0,0900006482559998
FDA-2016-N-0832-0051,FDA,FDA-2016-N-0832,Letter from FDA to Covington & Burling LLP,Other,Letter(s),2017-03-17T04:00:00Z,2017,3,2017-03-17T04:00:00Z,,2017-03-17T15:53:52Z,,0,0,0900006482510858
FDA-2016-N-0832-0048,FDA,FDA-2016-N-0832,"Letter from Office of the General Counsel to FDA OC and Covington & Burling, LLP (Phibro)",Other,Letter(s),2017-03-14T04:00:00Z,2017,3,2017-03-14T04:00:00Z,,2017-03-14T20:06:05Z,,0,0,09000064825077d6
FDA-2016-N-0832-0050,FDA,FDA-2016-N-0832,"Letter from FDA Office of Scientific Integrity to Covington & Burling, LLP (Phibro) and Office of the Chief Counsel",Other,Letter(s),2017-03-14T04:00:00Z,2017,3,2017-03-14T04:00:00Z,,2017-03-14T20:29:29Z,,0,0,09000064825077d8
FDA-2016-N-0832-0049,FDA,FDA-2016-N-0832,"Follow up emails between FDA and Covington & Burling, LLP (Phibro)",Other,General Correspondence,2017-03-14T04:00:00Z,2017,3,2017-03-14T04:00:00Z,,2017-03-14T20:13:15Z,,0,0,09000064825077d7
FDA-2016-N-0832-0047,FDA,FDA-2016-N-0832,Letter from Covington & Burling LLP (Phibro) to FDA OC,Other,Letter(s),2017-03-14T04:00:00Z,2017,3,2017-03-14T04:00:00Z,,2017-03-14T20:00:44Z,,0,0,09000064825077d5